Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Dr. Hui Shao C.F.A., M.B.A., Ph.D.
Full Time Employees
773
Sector
Healthcare
Industry
Biotechnology
Address
Building No. 2 Beijing People's Republic of China 102600
IPO Date
Aug 5, 2021
Business
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Company News

  • YS Biopharma Announces Name Change to LakeShore Biopharma

  • YS Biopharma Announces Results of Extraordinary General Meeting

  • YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

  • YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

  • YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript

  • YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

  • YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

  • YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

  • YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

  • YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

  • YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

  • YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

  • YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

  • Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

  • YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

  • YS Biopharma Announces Appointment of New Directors

  • YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.

  • YS Biopharma Announces US$40 Million Private Placement Financing

  • Shareholders of YS Biopharma Announce an Extraordinary General Meeting

  • YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024